Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
Osamu Kano,1 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Konosuke Iwamoto,1 Tetsuro Nagaoka,1 Takehisa Hirayama,1 Ken Miura,1 Riya Nagata,1 Tetsuhito Kiyozuka,2 Jo Aoyagi,2 Ryuta Sato,2 Teruo Eguchi,3 Ken Ikeda,1 Yasuo Iwasaki11Department of Neurology, Toho University Omori Medica...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2013
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3e58c3f1f8fe4ae58aa88921591e9297 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3e58c3f1f8fe4ae58aa88921591e9297 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3e58c3f1f8fe4ae58aa88921591e92972021-12-02T01:05:14ZClinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil1176-63281178-2021https://doaj.org/article/3e58c3f1f8fe4ae58aa88921591e92972013-02-01T00:00:00Zhttp://www.dovepress.com/clinically-meaningful-treatment-responses-after-switching-to-galantami-a12219https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Osamu Kano,1 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Konosuke Iwamoto,1 Tetsuro Nagaoka,1 Takehisa Hirayama,1 Ken Miura,1 Riya Nagata,1 Tetsuhito Kiyozuka,2 Jo Aoyagi,2 Ryuta Sato,2 Teruo Eguchi,3 Ken Ikeda,1 Yasuo Iwasaki11Department of Neurology, Toho University Omori Medical Center, 2Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations Mishuku Hospital, 3Sakura-kai Medical Group, Tokyo, JapanAbstract: Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy compared with increasing the dose of donepezil. This report discusses two studies conducted to evaluate treatment with galantamine and memantine with respect to cognitive benefits and caregiver evaluations in patients with AD receiving donepezil 5 mg/day for more than 6 months. Patients with mild or moderate AD (scores 10–22 on the Mini-Mental State Examination) were enrolled in the Galantamine Switch study and switched to galantamine (maximum doses 16 mg versus 24 mg). Patients with moderate to severe AD (Mini-Mental State Examination scores 3–14) were enrolled in the Donepezil Increase versus Additional Memantine study and either had their donepezil dose increased to 10 mg/day or memantine 20 mg/day added to their existing donepezil dose. Patients received the study treatment for 28 weeks and their Disability Assessment for Dementia, Mental Function Impairment Scale, Cohen-Mansfield Agitation Inventory, and Neuropsychiatric Inventory scores were assessed with assistance from their caregivers. For the Galantamine Switch study after 8 weeks, agitation evaluated by the Cohen-Mansfield Agitation Inventory improved in both the 16 mg and 24 mg groups compared with baseline. However, there were no significant differences between the two galantamine groups. Agitation was also less in patients in the additional memantine group than in the donepezil increase group. In summary, switching to galantamine from donepezil and addition of memantine in patients with AD receiving donepezil were both safe and meaningful treatment options, and particularly efficacious for suppression of agitation.Keywords: Alzheimer’s disease, galantamine, memantine, donepezil, agitation, acetylcholinesterase inhibitorsKano OIto HTakazawa TKawase YMurata KIwamoto KNagaoka THirayama TMiura KNagata RKiyozuka TAoyagi JSato REguchi TIkeda KIwasaki YDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 259-265 (2013) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 |
| spellingShingle |
Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kano O Ito H Takazawa T Kawase Y Murata K Iwamoto K Nagaoka T Hirayama T Miura K Nagata R Kiyozuka T Aoyagi J Sato R Eguchi T Ikeda K Iwasaki Y Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| description |
Osamu Kano,1 Hirono Ito,1 Takanori Takazawa,1 Yuji Kawase,1 Kiyoko Murata,1 Konosuke Iwamoto,1 Tetsuro Nagaoka,1 Takehisa Hirayama,1 Ken Miura,1 Riya Nagata,1 Tetsuhito Kiyozuka,2 Jo Aoyagi,2 Ryuta Sato,2 Teruo Eguchi,3 Ken Ikeda,1 Yasuo Iwasaki11Department of Neurology, Toho University Omori Medical Center, 2Department of Neurology, Federation of National Public Service Personnel Mutual Aid Associations Mishuku Hospital, 3Sakura-kai Medical Group, Tokyo, JapanAbstract: Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy compared with increasing the dose of donepezil. This report discusses two studies conducted to evaluate treatment with galantamine and memantine with respect to cognitive benefits and caregiver evaluations in patients with AD receiving donepezil 5 mg/day for more than 6 months. Patients with mild or moderate AD (scores 10–22 on the Mini-Mental State Examination) were enrolled in the Galantamine Switch study and switched to galantamine (maximum doses 16 mg versus 24 mg). Patients with moderate to severe AD (Mini-Mental State Examination scores 3–14) were enrolled in the Donepezil Increase versus Additional Memantine study and either had their donepezil dose increased to 10 mg/day or memantine 20 mg/day added to their existing donepezil dose. Patients received the study treatment for 28 weeks and their Disability Assessment for Dementia, Mental Function Impairment Scale, Cohen-Mansfield Agitation Inventory, and Neuropsychiatric Inventory scores were assessed with assistance from their caregivers. For the Galantamine Switch study after 8 weeks, agitation evaluated by the Cohen-Mansfield Agitation Inventory improved in both the 16 mg and 24 mg groups compared with baseline. However, there were no significant differences between the two galantamine groups. Agitation was also less in patients in the additional memantine group than in the donepezil increase group. In summary, switching to galantamine from donepezil and addition of memantine in patients with AD receiving donepezil were both safe and meaningful treatment options, and particularly efficacious for suppression of agitation.Keywords: Alzheimer’s disease, galantamine, memantine, donepezil, agitation, acetylcholinesterase inhibitors |
| format |
article |
| author |
Kano O Ito H Takazawa T Kawase Y Murata K Iwamoto K Nagaoka T Hirayama T Miura K Nagata R Kiyozuka T Aoyagi J Sato R Eguchi T Ikeda K Iwasaki Y |
| author_facet |
Kano O Ito H Takazawa T Kawase Y Murata K Iwamoto K Nagaoka T Hirayama T Miura K Nagata R Kiyozuka T Aoyagi J Sato R Eguchi T Ikeda K Iwasaki Y |
| author_sort |
Kano O |
| title |
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| title_short |
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| title_full |
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| title_fullStr |
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| title_full_unstemmed |
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil |
| title_sort |
clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with alzheimer’s disease receiving donepezil |
| publisher |
Dove Medical Press |
| publishDate |
2013 |
| url |
https://doaj.org/article/3e58c3f1f8fe4ae58aa88921591e9297 |
| work_keys_str_mv |
AT kanoo clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT itoh clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT takazawat clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT kawasey clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT muratak clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT iwamotok clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT nagaokat clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT hirayamat clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT miurak clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT nagatar clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT kiyozukat clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT aoyagij clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT sator clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT eguchit clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT ikedak clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil AT iwasakiy clinicallymeaningfultreatmentresponsesafterswitchingtogalantamineandwithadditionofmemantineinpatientswithalzheimeramprsquosdiseasereceivingdonepezil |
| _version_ |
1718403310368587776 |